Literature DB >> 7870687

In vitro and in vivo evaluation in dogs and pigs of a hydrophilic matrix containing propylthiouracil.

L Kabanda1, R A Lefebvre, H J Van Bree, J P Remon.   

Abstract

A hydrophilic matrix tablet containing 300 mg of propylthiouracil was formulated with several types of hydroxypropylmethylcellulose. The influence of polymer and drug granule particle size, polymer concentration, crystallinity and geometry of the polymer particles, the polymer incorporation outside or inside the granule, addition of a filler and tablet hardness were studied. Polymer concentration, polymer particle size and geometry, filler addition and type of the filler used had a major influence on in vitro drug dissolution profiles. The bioavailability of propylthiouracil in dogs from the hydrophilic matrices investigated was low, because of the short gastro-intestinal transit times of the matrix tablets in the dogs. The matrix tablets reached the colon in fasted dogs within 2-3 hours after administration. The results indicated the poor predictability of bioavailability experiments in dogs with hydrophilic matrices. Although the bioavailability data in pigs seemed promising, a transit time study revealed a long stomach residence time of the matrix tablets in pigs. These data suggested that pigs are an inappropriate animal model for bioavailability studies of erodible matrix tablets.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7870687     DOI: 10.1023/a:1018982409661

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

1.  [Effect of technologic factors on the release of vincamine incorporated into hydrophilic matrices].

Authors:  K Ventouras; J Boucherat; P Buri
Journal:  Pharm Acta Helv       Date:  1977

2.  Pharmacokinetics of propylthiouracil in man after intravenous infusion.

Authors:  J P Kampmann
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  ABSPLOTS: a LOTUS 123 spreadsheet for calculating and plotting drug absorption rates.

Authors:  R C Shumaker; H Boxenbaum; G A Thompson
Journal:  Pharm Res       Date:  1988-04       Impact factor: 4.200

4.  The pharmacokinetics of propylthiouracil.

Authors:  J Kampmann; L Skovsted
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-11

5.  The dog as a quantitative model for evaluation of nondisintegrating sustained-release tablets.

Authors:  W A Cressman; D Sumner
Journal:  J Pharm Sci       Date:  1971-01       Impact factor: 3.534

6.  In vivo pharmacodynamic evaluation of oral dosage forms by whole body liquid scintillometry.

Authors:  G Hecht; J E Christian; G S Banker
Journal:  J Pharm Sci       Date:  1966-07       Impact factor: 3.534

7.  Gastrointestinal transit of nondisintegrating, nonerodible oral dosage forms in pigs.

Authors:  M Hossain; W Abramowitz; B J Watrous; G J Szpunar; J W Ayres
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

8.  Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac.

Authors:  P C Smith; P N Langendijk; J A Bosso; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

9.  Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation.

Authors:  D R Abernethy; D J Greenblatt; B Ameer; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1985-08       Impact factor: 4.030

10.  Pharmacokinetics of propylthiouracil upon p.o. administration in man.

Authors:  H P Ringhand; W A Ritschel; M C Meyer; A B Straughn; T Hardt
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.